Lilly study demonstrates further benefits of Cialis

Lilly has announced data from a new trial that further adds to the positive clinical profile of its erectile dysfunction therapy Cialis.

Study results published in the Journal of Sexual Medicine showed that a greater percentage of men who had an incomplete response to as-needed PDE5 inhibitor treatment returned to normal erectile function when given Cialis once daily than those receiving a placebo.

Cialis also significantly improved erectile function scores versus placebo among this patient group, thus meeting both its primary and secondary goals in the trial.

Study author Dr Edward Kim of the University of Tennessee Graduate School of Medicine said: "We believe the study outcome will help prescribers make better informed decisions when treating their patients."

Lilly's drug is also indicated for use among men with the signs and symptoms of benign prostatic hyperplasia, with a study earlier this year showing that a combination of Cialis and finasteride can aid patients with lower urinary tract symptoms of benign prostatic hyperplasia and enlarged prostates.